Genmab — Maj 2017
-
Selv om vi har svar på spørgsmålet, så tåler det en gentagelse.
-
-
-
And AXL-ADC, you are already at third dose cohort people, so we are progressing towards very quickly and that means that we don't run into toxicity that is not manageable, so we think actually that we have an active product here, we can already see that and hopefully more data an overview of going with AXL-ADC next year not this year. So, it's very, very good progress in the dose escalation
-
Det mangler vi et spørgsmål omkring.
-
Tak Sukker.
-
Vi er ved at være på plads.
-
Du ruller dropdown ned. Finder Q&A chat 11. maj. Skriver dit spørgsmål.
-
Jeg poster det så til Jan med mindre der er flere som har spurgt om det samme.
-
Vi er nu 229 besøgende i Gen-chatten, historik og Q&A. Det er et meget velbesøgt investormøde fra Danmark,Norge, Holland,
-
Italien, Rusland, Sverige, Tyskland og Schweiz.
-
Og Luxemborg.
-
Plus Thailand og Zambia.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind